Clearside Biomedical Announces License Agreement with Aura Biosciences for Suprachoroidal Space Microinjector™ Designed to Optimize Ocular Oncology Drug Delivery
Aura is developing a novel class of therapies, viral nanoparticle conjugates, designed to selectively bind and eliminate cancer cells without damaging surrounding normal tissues. Aura is licensing Clearside’s proprietary SCS Microinjector as a potential non-surgical alternative to intravitreal delivery of Aura’s proprietary anti-cancer drug candidates, which may enable the delivery of higher concentrations using a lower dose to the choroid and adjacent areas. If the collaboration proves successful following preclinical and proof-of-concept studies, Aura may utilize the SCS Microinjector for certain future development programs.
“Clearside is committed to expanding the global reach of our SCS injection platform, and this collaboration with Aura broadens the use of our technology into the ocular oncology space,” said George Lasezkay, Pharm.D., J.D., Interim Chief Executive Officer and Board Member of Clearside. “Drug delivery to the SCS potentially offers several key advantages compared to intravitreal, periocular or subretinal injections, including repeatable, non-surgical drug administration to the SCS and target tissues in the retina and choroid, avoidance of non-targeted tissues, and strong bioavailability and durability. We believe Aura is an ideal partner for our targeted SCS Microinjector that has the potential to optimize dosing and administration of their ocular anti-cancer drug candidates, with the goal of bringing promising new treatments to patients suffering from ocular cancers such as choroidal melanoma.”
Pursuant to the licensing agreement, Clearside is eligible to receive payments related to pre-specified development, regulatory and sales milestones, as well as royalties on product sales that utilize the SCS Microinjector.
Clearside Biomedical Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include expectations regarding the potential benefits of the SCS injection platform and the potential approval and commercialization of XIPERE for the treatment of macular edema associated with uveitis. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Clearside’s Annual Report on Form 10-K for the year ended
Investor and Media Contacts:
Source: Clearside Biomedical, Inc.